Eli Lilly Reports Positive Results for Exenatide in Treatment of Type 2 Diabetes

Strategic Insights -

Type 2 diabetes continues to be a growing concern for healthcare providers and patients worldwide. Eli Lilly and Company (LLY) and its partners have made significant strides in developing innovative treatments for this condition, with the latest results showing that exenatide, a medication in a new class of incretin mimetics, demonstrates efficacy in controlling blood sugar levels as effectively as insulin for patients with type 2 diabetes. In a recent long-term clinical trial involving 501 participants, exenatide was found to improve blood sugar levels and reduce body weight, with 32% of patients achieving the target hemoglobin A1C (HbA1C) of 7% or less. The results of the study, presented at the 42nd annual meeting of the European Association of the Study of Diabetes (EASD), indicate that exenatide is a promising treatment option for patients with type 2 diabetes who have failed to achieve acceptable blood sugar control on oral medications.

Key Takeaways:

  • Exenatide, an incretin mimetic, demonstrates efficacy in controlling blood sugar levels as effectively as insulin for patients with type 2 diabetes.
  • The long-term clinical trial involved 501 participants and showed improvements in blood sugar levels and body weight for patients using exenatide.
  • 32% of patients treated with exenatide achieved the target HbA1C of 7% or less, compared to 24% in the biphasic insulin aspart group.
  • Exenatide lowered HbA1C by 1.04% while biphasic insulin aspart lowered HbA1C by 0.89%.
  • Patients treated with exenatide experienced an average weight reduction of 2.5 kilograms (5.5 pounds), while those receiving biphasic insulin aspart gained an average of 2.9 kilograms (6.4 pounds).
  • Exenatide reduced peak blood sugar levels after meals and had low rates of daytime and nighttime hypoglycemia.
  • The most common adverse event for exenatide was nausea, experienced by 33.2% of patients, which was generally mild-to-moderate and tended to decrease in frequency and severity over time.

Statistics:

  • 501 participants were enrolled in the long-term clinical trial involving exenatide.
  • 32% of patients treated with exenatide achieved the target HbA1C of 7% or less.
  • Exenatide lowered HbA1C by 1.04% and reduced fasting blood glucose by 1.8 mmol/L.
  • Patients treated with exenatide experienced an average weight reduction of 2.5 kilograms (5.5 pounds).
  • Biphasic insulin aspart gained an average of 2.9 kilograms (6.4 pounds) and had a higher rate of weight gain.

Sources:

  • European Association of the Study of Diabetes (EASD)
  • American Diabetes Association (ADA)
  • International Diabetes Federation (IDF)
  • U.S. Food and Drug Administration (FDA)
  • NewsRx.com